Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial

NCT00061464 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00061464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00061464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2003
Completion date
February 28, 2006
Enrollment
48
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung